520.3K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Darrin M. Beaupre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 185,000 | 185,000 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Andres Ruiz Briseno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Michael Anthony White | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 185,000 | 185,000 | - | - | Stock Option (right to buy) | |
| Stuart Dorman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.52 per share. | 18 Feb 2025 | 12,808 | 690,695 (3%) | 0% | 19.5 | 250,012 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 12,808 | 182,192 | - | - | Stock Option (right to buy) | |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 47,060 | 1,360 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2024 | 6,424 | 41,186 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 27 Jun 2024 | 47,060 | 63,484 (0%) | 0% | 7.0 | 329,891 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.34 per share. | 27 Jun 2024 | 6,424 | 16,424 (0%) | 0% | 13.3 | 85,696 | Common Stock |
| Terry Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Catherine J. Mackey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Scott W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Malcolm Garret Hampton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Michael Anthony White | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.23 per share. | 29 May 2024 | 27,649 | 851 (0%) | 0% | 36.2 | 1,001,588 | Common Stock |
| Michael Anthony White | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 28,500 | 64,000 | - | - | Stock Option (right to buy) | |
| Michael Anthony White | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.78 per share. | 29 May 2024 | 851 | 0 (0%) | 0% | 36.8 | 31,297 | Common Stock |
| Michael Anthony White | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.86 per share. | 29 May 2024 | 28,500 | 28,500 (0%) | 0% | 12.9 | 366,510 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 14 May 2024 | 56,711 | 734,598 (3%) | 0% | 4.3 | 244,424 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 34,433 | 49,454 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 83,856 | 83,887 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 56,711 | 167,743 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.37 per share. | 14 May 2024 | 4,349 | 677,887 (3%) | 0% | 42.4 | 184,250 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.73 per share. | 14 May 2024 | 30,084 | 682,236 (3%) | 0% | 41.7 | 1,255,505 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 14 May 2024 | 34,433 | 712,320 (3%) | 0% | 4.3 | 148,406 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.12 per share. | 14 May 2024 | 503 | 677,887 (3%) | 0% | 44.1 | 22,191 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 43.48 per share. | 14 May 2024 | 29,761 | 678,390 (3%) | 0% | 43.5 | 1,293,934 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.57 per share. | 14 May 2024 | 53,592 | 708,151 (3%) | 0% | 42.6 | 2,281,631 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 14 May 2024 | 83,856 | 761,743 (3%) | 0% | 4.3 | 361,419 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.84 per share. | 14 May 2024 | 2,303 | 677,887 (3%) | 0% | 41.8 | 96,348 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 41.60 per share. | 14 May 2024 | 54,408 | 680,190 (3%) | 0% | 41.6 | 2,263,433 | Common Stock |
| Darrin M. Beaupre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 480,000 | 480,000 | - | - | Stock Option (right to buy) | |
| Andres Ruiz Briseno | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Jason Throne | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 125,500 | 125,500 | - | - | Stock Option (right to buy) | |
| Michael Anthony White | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| Ruiz Briseno Andres | See Remarks | Sale of securities on an exchange or to another person at price $ 46.02 per share. | 09 Feb 2024 | 2,000 | 24,531 (0%) | 0% | 46.0 | 92,045 | Common Stock |
| S. Yujiro Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 08 Feb 2024 | 75,815 | 753,702 (3%) | 0% | 4.3 | 326,763 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.54 per share. | 08 Feb 2024 | 23,557 | 677,887 (3%) | 0% | 45.5 | 1,072,715 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 08 Feb 2024 | 23,557 | 701,444 (3%) | 0% | 4.3 | 101,531 | Common Stock |
| Yujiro Hata S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.15 per share. | 08 Feb 2024 | 75,815 | 677,887 (3%) | 0% | 45.1 | 3,422,835 | Common Stock |
| Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 23,557 | 224,454 | - | - | Stock Option (right to buy) | |
| Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 75,815 | 248,011 | - | - | Stock Option (right to buy) | |
| Hata Yujiro S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 01 Feb 2024 | 4 | 677,887 (3%) | 0% | 45 | 180 | Common Stock |
| Hata Yujiro S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 01 Feb 2024 | 624 | 677,891 (3%) | 0% | 45 | 28,080 | Common Stock |
| Hata Yujiro S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 628 | 323,826 | - | - | Stock Option (right to buy) | |
| Hata S. Yujiro | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 01 Feb 2024 | 628 | 678,515 (3%) | 0% | 4.3 | 2,707 | Common Stock |
| Ruiz Briseno Andres | See Remarks | Sale of securities on an exchange or to another person at price $ 42.02 per share. | 22 Jan 2024 | 2,000 | 26,531 (0%) | 0% | 42.0 | 84,050 | Common Stock |
| Ruiz Briseno Andres | See Remarks | Sale of securities on an exchange or to another person at price $ 38.01 per share. | 12 Jan 2024 | 2,000 | 28,531 (0%) | 0% | 38.0 | 76,026 | Common Stock |
| Hata Yujiro S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 12 Jan 2024 | 12,261 | 677,887 (3%) | 0% | 40.0 | 490,913 | Common Stock |
| S. Hata Yujiro | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2024 | 62,739 | 324,454 | - | - | Stock Option (right to buy) | |
| Yujiro Hata S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.17 per share. | 12 Jan 2024 | 62,739 | 677,887 (3%) | 0% | 40.2 | 2,519,968 | Common Stock |
| S. Yujiro Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2024 | 12,261 | 387,193 | - | - | Stock Option (right to buy) | |
| S. Hata Yujiro | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Jan 2024 | 62,739 | 740,626 (3%) | 0% | 4.3 | 270,405 | Common Stock |
| Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Jan 2024 | 12,261 | 690,148 (3%) | 0% | 4.3 | 52,845 | Common Stock |
| Yujiro Hata S. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.03 per share. | 15 Dec 2023 | 75,000 | 677,887 (3%) | 0% | 35.0 | 2,627,618 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 10,000 | 48,420 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 15 Dec 2023 | 10,000 | 0 (0%) | 0% | 35.0 | 350,371 | Common Stock |
| Throne Jason | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.34 per share. | 15 Dec 2023 | 10,000 | 10,000 (0%) | 0% | 13.3 | 133,400 | Common Stock |
| Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 75,000 | 399,454 | - | - | Stock Option (right to buy) | |
| Throne Jason | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 15 Dec 2023 | 10,000 | 10,000 (0%) | 0% | 7.0 | 70,100 | Common Stock |
| Throne Jason | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 10,000 | 47,610 | - | - | Stock Option (Right to Buy) | |
| Yujiro Hata S. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 15 Dec 2023 | 75,000 | 752,887 (3%) | 0% | 4.3 | 323,250 | Common Stock |
| Andres Ruiz Briseno | See Remarks | Sale of securities on an exchange or to another person at price $ 34.01 per share. | 14 Dec 2023 | 328 | 30,531 (0%) | 0% | 34.0 | 11,154 | Common Stock |
| Andres Ruiz Briseno | See Remarks | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 14 Dec 2023 | 1,672 | 30,859 (0%) | 0% | 34 | 56,848 | Common Stock |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.87 per share. | 29 Aug 2023 | 5,000 | 9,303 (0%) | 0% | 28.9 | 144,352 | Common Stock |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.40 per share. | 21 Aug 2023 | 978 | 14,303 (0%) | 0% | 26.4 | 25,819 | Common Stock |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.45 per share. | 16 Aug 2023 | 100 | 19,203 (0%) | 0% | 26.5 | 2,645 | Common Stock |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.38 per share. | 16 Aug 2023 | 3,822 | 15,281 (0%) | 0% | 26.4 | 100,820 | Common Stock |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.40 per share. | 16 Aug 2023 | 100 | 19,103 (0%) | 0% | 26.4 | 2,640 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.86 per share. | 10 Jul 2023 | 5,000 | 9,485 (0%) | 0% | 12.9 | 64,300 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 5,000 | 58,750 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 4,485 | 58,420 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 10 Jul 2023 | 9,485 | 0 (0%) | 0% | 23.0 | 218,178 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 10 Jul 2023 | 4,485 | 4,485 (0%) | 0% | 7.0 | 31,440 | Common Stock |
| Timothy M. Shannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Terry Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Catherine J. Mackey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Scott W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Malcolm Garret Hampton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 16,200 | 16,200 | - | - | Stock Option (right to buy) | |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 31 May 2023 | 3,553 | 3,553 (0%) | 0% | 7.0 | 24,907 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 31 May 2023 | 432 | 432 (0%) | 0% | 7.0 | 3,028 | Common Stock |
| Jason Throne | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 31 May 2023 | 432 | 0 (0%) | 0% | 23.0 | 9,938 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 3,553 | 62,905 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 432 | 66,458 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.02 per share. | 31 May 2023 | 3,553 | 0 (0%) | 0% | 23.0 | 81,792 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2023 | 500 | 66,890 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 22 May 2023 | 500 | 0 (0%) | 0% | 23 | 11,500 | Common Stock |
| Jason Throne | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 22 May 2023 | 500 | 500 (0%) | 0% | 7.0 | 3,505 | Common Stock |
| Paul Stone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2023 | 8,000 | 129,832 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 13 Apr 2023 | 8,000 | 21,803 (0%) | 0% | 4.6 | 36,960 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2023 | 11,601 | 474,454 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Apr 2023 | 11,601 | 677,887 (3%) | 0% | 4.3 | 50,000 | Common Stock |
| Darrin M. Beaupre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| Jason Throne | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Michael Anthony White | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 165,000 | 165,000 | - | - | Stock Option (right to buy) | |
| Timothy M. Shannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Terry Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott W. Morison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Malcolm Garret Hampton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Catherine J. Mackey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| Paul Stone | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 92,500 | 92,500 | - | - | Stock Option (right to buy) | |
| Jason Throne | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 63,750 | 63,750 | - | - | Stock Option (Right to Buy) | |
| Michael Anthony White | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 92,500 | 92,500 | - | - | Stock Option (right to buy) | |
| Michael Anthony White | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2021 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.85 per share. | 04 Oct 2021 | 500 | 79,789 (0%) | 0% | 25.8 | 12,924 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.08 per share. | 04 Oct 2021 | 1,500 | 80,289 (0%) | 0% | 11.1 | 16,620 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.62 per share. | 04 Oct 2021 | 1,000 | 78,789 (0%) | 0% | 26.6 | 26,621 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2021 | 1,500 | 23,437 | - | - | Stock Option (Right to Buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 07 Sep 2021 | 116 | 78,905 (0%) | 0% | 4.3 | 500 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 4,313 | 24,937 | - | - | Stock Option (Right to Buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 7,071 | 59,048 | - | - | Stock Option (Right to Buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 116 | 66,119 | - | - | Stock Option (Right to Buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.67 per share. | 07 Sep 2021 | 200 | 78,789 (0%) | 0% | 27.7 | 5,534 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.41 per share. | 07 Sep 2021 | 11,184 | 78,989 (0%) | 0% | 27.4 | 306,559 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.08 per share. | 07 Sep 2021 | 4,313 | 90,173 (0%) | 0% | 11.1 | 47,788 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 07 Sep 2021 | 7,071 | 85,860 (0%) | 0% | 4.3 | 30,476 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.46 per share. | 07 Sep 2021 | 116 | 78,789 (0%) | 0% | 27.5 | 3,185 | Common Stock |
| Paul Stone | SVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.42 per share. | 07 Sep 2021 | 2,500 | 12,944 (0%) | 0% | 27.4 | 68,543 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 02 Sep 2021 | 10,000 | 78,789 (0%) | 0% | 25.1 | 250,943 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.96 per share. | 09 Aug 2021 | 11,100 | 89,189 (0%) | 0% | 23.0 | 254,863 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 1,500 | 66,235 | - | - | Stock Option (Right to Buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.52 per share. | 09 Aug 2021 | 400 | 88,789 (0%) | 0% | 23.5 | 9,406 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 09 Aug 2021 | 1,500 | 100,289 (0%) | 0% | 4.3 | 6,465 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 27 Jul 2021 | 5,000 | 108,789 (0%) | 0% | 4.3 | 21,550 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 5,000 | 67,735 | - | - | Stock Option (Right to Buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 5,000 | 39,500 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.15 per share. | 27 Jul 2021 | 10,000 | 98,789 (0%) | 0% | 25.1 | 251,460 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 27 Jul 2021 | 5,000 | 103,789 (0%) | 0% | 6.9 | 34,600 | Common Stock |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 25.17 per share. | 27 Jul 2021 | 10,000 | 0 (0%) | 0% | 25.2 | 251,683 | Common Stock |
| Jason Throne | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 10,000 | 62,610 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.34 per share. | 27 Jul 2021 | 10,000 | 10,000 (0%) | 0% | 13.3 | 133,400 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.20 per share. | 06 Jul 2021 | 1,400 | 98,889 (0%) | 0% | 22.2 | 31,082 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 1,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.76 per share. | 06 Jul 2021 | 100 | 98,789 (0%) | 0% | 22.8 | 2,276 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 06 Jul 2021 | 1,500 | 100,289 (0%) | 0% | 6.9 | 10,380 | Common Stock |
| Jason Throne | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.01 per share. | 06 Jul 2021 | 7,610 | 7,610 (0%) | 0% | 7.0 | 53,346 | Common Stock |
| Jason Throne | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 2,390 | 72,610 | - | - | Stock Option (Right to Buy) | |
| Jason Throne | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 7,610 | 67,390 | - | - | Stock Option (right to buy) | |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 22.67 per share. | 06 Jul 2021 | 359 | 0 (0%) | 0% | 22.7 | 8,140 | Common Stock |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 22.16 per share. | 06 Jul 2021 | 2,031 | 359 (0%) | 0% | 22.2 | 45,015 | Common Stock |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 22.68 per share. | 06 Jul 2021 | 1,142 | 2,390 (0%) | 0% | 22.7 | 25,895 | Common Stock |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 22.16 per share. | 06 Jul 2021 | 6,468 | 3,532 (0%) | 0% | 22.2 | 143,357 | Common Stock |
| Jason Throne | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.34 per share. | 06 Jul 2021 | 2,390 | 10,000 (0%) | 0% | 13.3 | 31,883 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2021 | 1,107 | 49,893 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 16 Jun 2021 | 1,107 | 99,896 (0%) | 0% | 6.9 | 7,660 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.47 per share. | 16 Jun 2021 | 1,107 | 98,789 (0%) | 0% | 22.5 | 24,873 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 16 Jun 2021 | 3,893 | 102,682 (0%) | 0% | 6.9 | 26,940 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.49 per share. | 16 Jun 2021 | 3,893 | 98,789 (0%) | 0% | 22.5 | 87,540 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2021 | 3,893 | 46,000 | - | - | Stock Option (right to buy) | |
| Timothy M. Shannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Terry Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Malcolm Garret Hampton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 07 Jun 2021 | 1,500 | 98,789 (0%) | 0% | 20.2 | 30,333 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 1,500 | 51,000 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 07 Jun 2021 | 1,500 | 100,289 (0%) | 0% | 6.9 | 10,380 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 11 May 2021 | 5,000 | 98,789 (0%) | 0% | 20.2 | 101,093 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 5,000 | 52,500 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 11 May 2021 | 5,000 | 103,789 (0%) | 0% | 6.9 | 34,600 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 195,000 | 195,000 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Paul Stone | SVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Jason Throne | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 52,500 | 52,500 | - | - | Stock Option (right to buy) | |
| Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.74 per share. | 09 Feb 2021 | 5,000 | 98,789 (0%) | 0% | 20.7 | 103,697 | Common Stock |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2021 | 5,000 | 57,500 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.92 per share. | 09 Feb 2021 | 5,000 | 103,789 (0%) | 0% | 6.9 | 34,600 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 08 Feb 2021 | 100 | 200 (0%) | 0% | 21.0 | 2,102 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 596 | 33,014 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 1,104 | 33,610 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 300 | 34,714 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 08 Feb 2021 | 596 | 0 (0%) | 0% | 21 | 12,516 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 08 Feb 2021 | 596 | 596 (0%) | 0% | 7.0 | 4,160 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 08 Feb 2021 | 1,104 | 0 (0%) | 0% | 21.0 | 23,234 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 08 Feb 2021 | 1,104 | 1,104 (0%) | 0% | 7.0 | 7,706 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 08 Feb 2021 | 200 | 0 (0%) | 0% | 21 | 4,200 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 08 Feb 2021 | 300 | 300 (0%) | 0% | 7.0 | 2,094 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 26 Jan 2021 | 1,123 | 2,501 (0%) | 0% | 7.0 | 7,839 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 1,123 | 35,014 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 377 | 61,760 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 18.79 per share. | 26 Jan 2021 | 800 | 0 (0%) | 0% | 18.8 | 15,034 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 26 Jan 2021 | 1,701 | 800 (0%) | 0% | 18.3 | 31,124 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 26 Jan 2021 | 377 | 1,378 (0%) | 0% | 4.6 | 1,742 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 22 Dec 2020 | 8,000 | 666,286 (3%) | 0% | 4.3 | 34,480 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2020 | 8,000 | 486,055 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 7,750 | 72,735 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 18 Dec 2020 | 7,750 | 98,789 (0%) | 0% | 4.3 | 33,403 | Common Stock |
| Paul Stone | SVP, Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 11 Dec 2020 | 444 | 15,444 (0%) | 0% | 0 | Common Stock | |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 15.55 per share. | 04 Dec 2020 | 1,579 | 0 (0%) | 0% | 15.5 | 24,548 | Common Stock |
| Jason Throne | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 14.66 per share. | 04 Dec 2020 | 400 | 1,579 (0%) | 0% | 14.7 | 5,862 | Common Stock |
| Jason Throne | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Malcolm Garret Hampton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 17 Jun 2020 | 3,100 | 18,100 (0%) | 0% | 4.6 | 14,322 | Common Stock |
| Paul Stone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2020 | 3,100 | 137,832 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.95 per share. | 17 Jun 2020 | 600 | 15,000 (0%) | 0% | 19.9 | 11,968 | Common Stock |
| Paul Stone | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.50 per share. | 17 Jun 2020 | 2,500 | 15,600 (0%) | 0% | 17.5 | 43,749 | Common Stock |
| Timothy M. Shannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Terry Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Scott W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 3,887 | 62,510 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 16 Jun 2020 | 3,887 | 3,887 (0%) | 0% | 4.6 | 17,958 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 16 Jun 2020 | 2,863 | 6,750 (0%) | 0% | 7.0 | 19,984 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 14.93 per share. | 16 Jun 2020 | 6,750 | 0 (0%) | 0% | 14.9 | 100,761 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 16 Jun 2020 | 373 | 373 (0%) | 0% | 4.6 | 1,723 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 19.91 per share. | 16 Jun 2020 | 373 | 0 (0%) | 0% | 19.9 | 7,428 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 2,863 | 36,137 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 373 | 62,137 | - | - | Stock Option (right to buy) | |
| Jason Throne | VP, General Counsel | Sale of securities on an exchange or to another person at price $ 8.66 per share. | 04 Jun 2020 | 2,205 | 0 (0%) | 0% | 8.7 | 19,087 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 10.11 per share. | 02 Jun 2020 | 104 | 0 (0%) | 0% | 10.1 | 1,051 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 9.73 per share. | 02 Jun 2020 | 333 | 104 (0%) | 0% | 9.7 | 3,241 | Common Stock |
| Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 8.55 per share. | 02 Jun 2020 | 408 | 437 (0%) | 0% | 8.5 | 3,487 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 15 Apr 2020 | 47,564 | 658,286 (3%) | 0% | 4.3 | 205,001 | Common Stock |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2020 | 47,564 | 494,055 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2020 | 5,000 | 140,932 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 30 Mar 2020 | 5,000 | 15,000 (0%) | 0% | 4.6 | 23,100 | Common Stock |
| Julie Hambleton | SVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Michael Dillon | SVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 215,000 | 215,000 | - | - | Stock Option (right to buy) | |
| Mark Lackner | SVP, Head of Biology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Paul Stone | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2020 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Wendy L. Yarno | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2019 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Jason Throne | VP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2019 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| John D. Diekman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Timothy M. Shannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Terry Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 1,250 | 1,250 | - | - | Stock Option (right to buy) | |
| Jeffrey Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 1,250 | 1,250 | - | - | Stock Option (right to buy) | |
| Scott W. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 1,250 | 1,250 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2019 | 15,000 | 541,619 | - | - | Stock Option (right to buy) | |
| Yujiro S. Hata | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 30 Jul 2019 | 15,000 | 610,722 (3%) | 0% | 4.3 | 64,650 | Common Stock |
| Jeffrey Hager | SVP, Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2019 | 5,197 | 10,396 | - | - | Stock Option (right to buy) | |
| Jeffrey Hager | SVP, Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 26 Jul 2019 | 5,197 | 127,853 (0%) | 0% | 4.3 | 22,399 | Common Stock |
| Paul Stone | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2019 | 10,000 | 145,932 | - | - | Stock Option (right to buy) | |
| Paul Stone | SVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 26 Jul 2019 | 10,000 | 10,000 (0%) | 0% | 4.6 | 46,200 | Common Stock |
| Jeffrey Hager | SVP, Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 19 Jun 2019 | 7,145 | 122,656 (0%) | 0% | 4.3 | 30,795 | Common Stock |
| Jeffrey Hager | SVP, Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2019 | 7,145 | 33,275 | - | - | Stock Option (right to buy) | |
| Jeffrey Hager | SVP, Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2019 | 8,628 | 40,420 | - | - | Stock Option (right to buy) | |
| Jeffrey Hager | SVP, Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 19 Jun 2019 | 8,628 | 115,511 (0%) | 0% | 4.3 | 37,187 | Common Stock |
| John D. Diekman | Director | 28 May 2019 | 1,721,898 | 2,026,098 (9%) | 8% | - | Common Stock | ||
| John D. Diekman | Director | 28 May 2019 | 71,745 | 84,420 (0%) | 0% | - | Common Stock | ||
| John D. Diekman | Director | 28 May 2019 | 578,447 | 2,604,545 (12%) | 2% | - | Common Stock | ||
| John D. Diekman | Director | 28 May 2019 | 24,101 | 0 | - | - | Series B Preferred Stock | ||
| John D. Diekman | Director | 28 May 2019 | 71,745 | 0 | - | - | Series A Preferred Stock | ||
| John D. Diekman | Director | 28 May 2019 | 578,447 | 0 | - | - | Series B Preferred Stock | ||
| John D. Diekman | Director | 28 May 2019 | 1,721,898 | 0 | - | - | Series A Preferred Stock | ||
| John D. Diekman | Director | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 28 May 2019 | 10,000 | 118,521 (0%) | 0% | 10 | 100,000 | Common Stock |
| John D. Diekman | Director | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 28 May 2019 | 240,000 | 2,844,545 (13%) | 1% | 10 | 2,400,000 | Common Stock |
| John D. Diekman | Director | 28 May 2019 | 24,101 | 108,521 (0%) | 0% | - | Common Stock | ||
| Timothy M. Shannon | Director | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 28 May 2019 | 400,000 | 2,660,713 (13%) | 1% | 10 | 4,000,000 | Common Stock |
| Timothy M. Shannon | Director | 28 May 2019 | 1,658,164 | 0 | - | - | Series A Preferred Stock | ||
| Timothy M. Shannon | Director | 28 May 2019 | 602,549 | 0 | - | - | Series B Preferred Stock | ||
| Timothy M. Shannon | Director | 28 May 2019 | 1,658,164 | 1,658,164 (8%) | 8% | - | Common Stock | ||
| Timothy M. Shannon | Director | 28 May 2019 | 602,549 | 2,260,713 (11%) | 2% | - | Common Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 71,745 | 84,420 (0%) | 0% | - | Common Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 24,101 | 108,521 (0%) | 0% | - | Common Stock | ||
| Paul Stone | SVP, General Counsel | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 28 May 2019 | 240,000 | 2,844,545 (13%) | 1% | 10 | 2,400,000 | Common Stock |
| Paul Stone | SVP, General Counsel | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 28 May 2019 | 10,000 | 118,521 (0%) | 0% | 10 | 100,000 | Common Stock |
| Paul Stone | SVP, General Counsel | 28 May 2019 | 24,101 | 0 | - | - | Series B Preferred Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 578,447 | 0 | - | - | Series B Preferred Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 71,745 | 0 | - | - | Series A Preferred Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 1,721,898 | 0 | - | - | Series A Preferred Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 1,721,898 | 2,026,098 (9%) | 8% | - | Common Stock | ||
| Paul Stone | SVP, General Counsel | 28 May 2019 | 578,447 | 2,604,545 (12%) | 2% | - | Common Stock |